Patients who show a risk for paroxysmal atrial fibrillation after SRAdoc® will be examined for fibrillation episodes with SRA24®. SRA24® automaticall finds occurring fibrillation episodes and saves the physician the time consuming search for them.
An effective screening with SRAdoc® identifies patients with previously unrecognized paroxysmal atrial fibrillation and can thus prevent strokes.
In Germany alone, there are approximately 1 million people with unrecognized and untreated paroxysmal atrial fibrillation. SRAdoc® is used to identify these in good time and to initiate an adequate therapy.
In patients with paroxysmal atrial fibrillation the probability to detect a fibrillation episode is increased with the prolongation of the recording time. But without a targeted pre-selection of the patients to be examined, the success to identify these patients will be kept within limits, even with recordings over several days.